Sudeep Pharma's Q2 FY 2025-26 Quarterly Results
- 06 Jan 2026
Result Summary
- Sudeep Pharma Ltd reported a 32.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were up by 31.7% QoQ and - - YoY.
- The net profit increased 49.6% QoQ and - - YoY.
- The earnings per share (EPS) of Sudeep Pharma Ltd stood at 4.2 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 172.83 | 130.08 | 0.00 | 32.9% | - |
Total Expenses | 113.29 | 86.00 | 0.00 | 31.7% | - |
Profit Before Tax | 59.53 | 44.07 | - | 35.1% | NaN% |
Tax | 12.76 | 12.80 | 0.00 | -0.3% | - |
Profit After Tax | 46.78 | 31.27 | 0.00 | 49.6% | - |
Earnings Per Share | 4.20 | 2.80 | 0.00 | 50.0% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sudeep Pharma Ltd is a company engaged in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. This sector typically involves the development of medicines and related healthcare products, although specific details about Sudeep Pharma's product lines and services are not provided in the current dataset. Recent major developments within the company or industry are also not available in the provided information. Typically, this industry is influenced by regulatory changes, innovation in drug development, and shifts in healthcare demands, but no specific events are noted for Sudeep Pharma Ltd.
Revenue
During the second quarter of the fiscal year 2026 (Q2FY26), Sudeep Pharma Ltd reported a total income of ₹172.83 crores. This represents a quarter-over-quarter (QoQ) increase of 32.9% from ₹130.08 crores in the first quarter of fiscal year 2026 (Q1FY26). Year-over-year (YoY) comparisons are not available as data for Q2FY25 was not provided. The significant QoQ increase indicates a substantial rise in revenue over the last quarter. Details about the sources of this income, such as product lines or geographical segments, are not disclosed in the data.
Profitability
In terms of profitability, Sudeep Pharma Ltd achieved a profit before tax of ₹59.53 crores in Q2FY26, which is a 35.1% increase from Q1FY26's figure of ₹44.07 crores. After accounting for taxes amounting to ₹12.76 crores, the profit after tax (PAT) stands at ₹46.78 crores, reflecting a noteworthy 49.6% QoQ increase from ₹31.27 crores in Q1FY26. Earnings per share (EPS) also rose from ₹2.80 in Q1FY26 to ₹4.20 in Q2FY26, marking a 50.0% increase. The tax expense remained relatively stable with a slight decrease of 0.3% QoQ. Year-over-year comparisons and trends are not available as data for Q2FY25 was not provided.
Operating Metrics
The financial data provided does not include specific operating metrics like production volumes, sales per product line, or efficiency ratios. However, the company’s total expenses for Q2FY26 were ₹113.29 crores, up by 31.7% from ₹86.00 crores in Q1FY26. This increase in expenses is slightly lower than the rise in total income, contributing to the improved profit margins observed in this quarter. Key financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio cannot be calculated due to the lack of data on market valuation, liabilities, and assets. As such, detailed insights into the company’s operational efficiency and financial health are limited from the provided data.